165 related articles for article (PubMed ID: 32877567)
1. Hepatitis C Virus Incidence in a Cohort in Medication-Assisted Treatment for Opioid Use Disorder in New York City.
Jordan AE; Cleland CM; Wyka K; Schackman BR; Perlman DC; Nash D
J Infect Dis; 2020 Sep; 222(Suppl 5):S322-S334. PubMed ID: 32877567
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C Virus (HCV) Care Continuum Outcomes and HCV Community Viral Loads Among Patients in an Opioid Treatment Program.
Jordan AE; Cleland CM; Schackman BR; Wyka K; Perlman DC; Nash D
J Infect Dis; 2020 Sep; 222(Suppl 5):S335-S345. PubMed ID: 32877560
[TBL] [Abstract][Full Text] [Related]
3. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users.
Tsui JI; Evans JL; Lum PJ; Hahn JA; Page K
JAMA Intern Med; 2014 Dec; 174(12):1974-81. PubMed ID: 25347412
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus prevalence and estimated incidence among new injectors during the opioid epidemic in New York City, 2000-2017: Protective effects of non-injecting drug use.
Des Jarlais DC; Arasteh K; Feelemyer J; McKnight C; Barnes DM; Perlman DC; Uuskula A; Cooper HLF; Tross S
Drug Alcohol Depend; 2018 Nov; 192():74-79. PubMed ID: 30243142
[TBL] [Abstract][Full Text] [Related]
5. Psychosocial Factors and the Care Cascade for Hepatitis C Treatment Colocated at a Syringe Service Program.
Winetsky D; Burack D; Antoniou P; Garcia B; Gordon P; Scherer M
J Infect Dis; 2020 Sep; 222(Suppl 5):S392-S400. PubMed ID: 32877544
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C seroconversion in methadone maintenance treatment programs in Wuhan, China.
Zhou W; Wang X; Zhou S; Xie N; Liu P; Luo L; Peng J; Liu M; Desrosiers A; Schottenfeld R; Chawarski MC
Addiction; 2015 May; 110(5):796-802. PubMed ID: 25529103
[TBL] [Abstract][Full Text] [Related]
7. Retention in buprenorphine treatment is associated with improved HCV care outcomes.
Norton BL; Beitin A; Glenn M; DeLuca J; Litwin AH; Cunningham CO
J Subst Abuse Treat; 2017 Apr; 75():38-42. PubMed ID: 28237052
[TBL] [Abstract][Full Text] [Related]
8. Low risk for hepatitis C seroconversion in methadone maintenance treatment.
Peles E; Schreiber S; Rados V; Adelson M
J Addict Med; 2011 Sep; 5(3):214-20. PubMed ID: 21844836
[TBL] [Abstract][Full Text] [Related]
9. Examination of the Hepatitis C Virus care continuum among individuals with an opioid use disorder in substance use treatment.
Brown JL; Gause NK; Lewis D; Winhusen T
J Subst Abuse Treat; 2017 May; 76():77-80. PubMed ID: 28162850
[TBL] [Abstract][Full Text] [Related]
10. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users.
Nolan S; Dias Lima V; Fairbairn N; Kerr T; Montaner J; Grebely J; Wood E
Addiction; 2014 Dec; 109(12):2053-9. PubMed ID: 25041346
[TBL] [Abstract][Full Text] [Related]
11. Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration.
Morris MD; Shiboski S; Bruneau J; Hahn JA; Hellard M; Prins M; Cox AL; Dore G; Grebely J; Kim AY; Lauer GM; Lloyd A; Rice T; Shoukry N; Maher L; Page K;
Clin Infect Dis; 2017 Apr; 64(7):860-869. PubMed ID: 28362947
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders.
Carey KJ; Huang W; Linas BP; Tsui JI
J Subst Abuse Treat; 2016 Jul; 66():54-9. PubMed ID: 26988423
[TBL] [Abstract][Full Text] [Related]
13. Test uptake and hepatitis C prevalence in 5483 Danish people in drug use treatment from 1996 to 2015: a registry-based cohort study.
Øvrehus A; Nielsen S; Hansen JF; Holm DK; Christensen P
Addiction; 2019 Mar; 114(3):494-503. PubMed ID: 30347471
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C Cascade of Care Among Pregnant Women on Opioid Agonist Pharmacotherapy Attending a Comprehensive Prenatal Program.
Page K; Leeman L; Bishop S; Cano S; Bakhireva LN
Matern Child Health J; 2017 Sep; 21(9):1778-1783. PubMed ID: 28699096
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C in a Mobile Low-Threshold Methadone Program.
Silva MJ; Pereira C; Loureiro R; Balsa C; Lopes P; Água-Doce I; Belo E; Martins HC; Coutinho R; Pádua E
Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):657-662. PubMed ID: 28151750
[TBL] [Abstract][Full Text] [Related]
16. Retention in Georgia opioid substitution therapy program and associated factors.
Ruadze E; Todadze K
Harm Reduct J; 2016 Dec; 13(1):35. PubMed ID: 27931232
[TBL] [Abstract][Full Text] [Related]
17. High hepatitis C incidence in relation to prescription opioid injection and poly-drug use: Assessing barriers to hepatitis C prevention.
Puzhko S; Roy É; Jutras-Aswad D; Artenie AA; Fortier E; Zang G; Bruneau J
Int J Drug Policy; 2017 Sep; 47():61-68. PubMed ID: 28666636
[TBL] [Abstract][Full Text] [Related]
18. Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation.
Jordan AE; Perlman DC; Cleland CM; Wyka K; Schackman BR; Nash D
J Clin Virol; 2020 Mar; 124():104285. PubMed ID: 32007842
[TBL] [Abstract][Full Text] [Related]
19. Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006-2013.
Jordan AE; Des Jarlais DC; Arasteh K; McKnight C; Nash D; Perlman DC
Drug Alcohol Depend; 2015 Jul; 152():194-200. PubMed ID: 25891230
[TBL] [Abstract][Full Text] [Related]
20. Development, validation, and potential applications of the hepatitis C virus injection-risk knowledge scale (HCV-IRKS) among young opioid users in New York City.
Quinn K; Fong C; Guarino H; Mateu-Gelabert P
Drug Alcohol Depend; 2019 Jan; 194():453-459. PubMed ID: 30503906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
